Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24: The REMS Program for Mavacamten
Author(s): Milind Y Desai Added: 1 year ago
AHA Conference 2024 - 22 month data from the risk evaluation and mitigation strategy (REMS) program for mavacamten (Camzyos; Bristol-Myers Squibb Company) in hypertrophic cardiomyopathy (HCM) patients.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from the REMS program for mavacamten.The REMS program investigated the safety and efficacy of… View more

Heart Failure
ESC 25: The ODYSSEY-HCM Study
Author(s): Milind Y Desai Added: 3 months ago
ESC Congress 2025 - ODYSSEY-HCM finds no improvements in patients with non-obstructive cardiomyopathy when treated with mavacamten.Dr Milind Desai (Cleveland Clinic, US) joins us to discuss findings from the ODYSSEY-HCM trial, evaluating the safety, tolerability, and efficacy of mavacamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy.The ODYSSEY-HCM study was a… View more

Heart Failure
AHA 24: The VALOR-HCM Trial
Author(s): Milind Y Desai Added: 1 year ago
AHA Conference 2024 - 128-week results of VALOR-HCM investigating mavacamten treatment for patients with hypertrophic cardiomyopathy (HCM) referred for septal reduction therapy (SRT) procedures.Dr Milind Desai (Cleveland Clinic, Ohio, US) joins us onsite at AHA Conference to discuss the findings from VALOR-HCM (NCT04349072).VALOR-HCM is a randomized, double-blind, placebo-controlled, phase 3… View more

Heart Failure
Emerging Therapies for Obstructive Hypertrophic Cardiomyopathy
Author(s): Emily Li-Wen Chu , Daniel Seung Kim , Ahmad Masri Added: 1 month ago

Heart Failure

Intervention
HFSA 24: The EMBARK HFpEF Trial
Author(s): Added: 1 year ago
HFSA 24 - We are joined virtually by Dr Sanjiv Shah to discuss the primary results from EMBARK HFpEF (NCT04766892).EMBARK HFpEF is a phase 2a proof-of-concept study assessing the safety, tolerability and preliminary efficacy of mavacamten treatment on myosin biomarkers in patients with heart failure with preserved ejection fractions (HFpEF) and elevated NT-proBNP.Interview Questions:What is the… View more

Heart Failure
MAPLE-HCM: Aficamten Outperforms Beta-Blocker in Obstructive Hypertrophic Cardiomyopathy
Added: 3 months ago Source:  Radcliffe Cardiology
Two phase 3 trials presented at the European Society of Cardiology Congress 2025 have provided new insights into the role of myosin inhibitors for hypertrophic cardiomyopathy (HCM), with one trial demonstrating superiority over standard care in obstructive HCM and another failing to meet its primary endpoints in the non-obstructive form of the disease.¹˒²The MAPLE-HCM trial found that the cardiac… View more

Guidelines & Statements

Heart Failure
Imaging Advances in Heart Failure
Author(s): Ritu Thamman , Naeimeh Hosseini , Marie-Luise Dikou , et al Added: 1 year ago

Heart Failure
Arrhythmias and Sudden Death: What is New in HCM?
Author(s): Deepthi Rajan , Christopher Ryan Zörner , Morten Lock Hansen , et al Added: 8 months ago

Heart Failure

Prevention & Chronic Conditions